Search

Your search keyword '"CRLCC Eugène Marquis (CRLCC)"' showing total 3 results
Start Over Author "CRLCC Eugène Marquis (CRLCC)" Journal annals of oncology
3 results on '"CRLCC Eugène Marquis (CRLCC)"'

1. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial

Author

Lionnel Geoffrois, Remy Delva, N. Houede, Frederic Rolland, Agnès Laplanche, J.-C. Eymard, B. Laguerre, Aude Flechon, Karim Fizazi, Stéphane Culine, D. Burcoveanu, G. Gravis, Christine Chevreau, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Léon Bérard [Lyon], Institut de Cancérologie de Lorraine - Alexis Vautrin (ICL), Institut Claudius Regaud, CRLCC Institut Claudius Regaud, CRLCC Eugène Marquis (CRLCC), Institut de cancérologie de l'Ouest - Paul Papin (ICO - Paul Papin), CRLCC Jean Godinot, CRLCC René Gauducheau, Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Institut Bergonié - CRLCC Bordeaux, Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1), Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Hôpital Saint-Louis, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut Bergonié [Bordeaux], Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)

Subjects
Male, Oncology, 030232 urology & nephrology, Salvage therapy, Kaplan-Meier Estimate, Deoxycytidine, Gastroenterology, Testicular Neoplasms/*drug therapy/mortality/pathology, 0302 clinical medicine, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Ifosfamide, Hematology, Middle Aged, Neoplasms, Germ Cell and Embryonal, Ifosfamide/administration & dosage, Chemotherapy regimen, 3. Good health, Treatment Outcome, Germ Cell and Embryonal/*drug therapy/mortality/secondary, Lymphatic Metastasis, 030220 oncology & carcinogenesis, medicine.drug, Adult, medicine.medical_specialty, [SDV.CAN]Life Sciences [q-bio]/Cancer, Drug Administration Schedule, Young Adult, 03 medical and health sciences, Testicular Neoplasms, Internal medicine, Deoxycytidine/administration & dosage/analogs & derivatives, medicine, Local/*drug therapy, Humans, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Progression-free survival, Survival rate, Salvage Therapy, business.industry, medicine.disease, Gemcitabine, Regimen, Neoplasm Recurrence, Cisplatin, Neoplasm Recurrence, Local, business, Cisplatin/administration & dosage, Febrile neutropenia
Abstract

International audience; BACKGROUND: The standard treatment of patients with metastatic germ-cell tumor (GCT) relapsing after first-line chemotherapy is based on a cisplatin and ifosfamide-containing three-drug regimen, which usually yields a complete response (CR) rate \textless50%. As gemcitabine consistently displayed activity in patients with advanced GCT and as synergy with cisplatin was reported, we integrated this drug into the salvage triplet regimen and assessed its activity in this phase II study. PATIENTS AND METHODS: The GIP regimen consisted in gemcitabine 1000 mg/m(2) day 1 and 5, ifosfamide 1200 mg/m(2)/day day 1-5, cisplatin 20 mg/m(2)/day day 1-5, and granulocyte colony-stimulating factor 263 mug/day day 7-15, repeated every 3 weeks for four cycles. Eligibility criteria were that patients had favorable prognostic factors to conventional-dose salvage chemotherapy including a testis primary tumor and a previous CR to first-line chemotherapy for metastatic disease. The primary end point was the CR rate and a two-stage Simon design was used. RESULTS: Thirty-seven patients were accrued and 29 (78%) achieved a favorable response, including a CR in 20 (54%) and a partial response with normalization of tumor markers (PRm-) in 9 (24%). With a median follow-up of 53 months (13-81), the 2-year overall survival rate is 73% (57%-84%) and the continuous progression-free survival rate is 51% (35%-66%). Myelosuppression was the main toxicity including febrile neutropenia in 8 (22%) patients and 18 (50%) cases required platelet infusion. No grade 3 and 4 peripheral neurotoxicity or renal toxicity occurred. Two patients died of treatment-related toxicity, one of them with cancer progression. CONCLUSION: In a multicenter context, four cycles of the GIP regimen achieved a high CR rate in patients with relapsed testicular GCT. The GIP regimen avoided severe neurotoxicity and yielded a high survival rate. CLINICAL TRIAL NUMBER: NCT00127049.

Published
2014

2. Correction to: Surgery in reference centers improves survival of sarcoma patients: a nationwide study

Author

M. Karanian-Philippe, Isabelle Ray-Coquard, A. Di Marco, J.-M. Guilloit, C. Perrin, M. Toulmonde, J.-P. Spano, G. Ferron, C. Le Pechoux, O. Collard, M. Rios, François Sirveaux, J. Guiramand, A. Dufresne, L. Chaigneau, C. Chevreau, S. Causeret, P. Gimbergues, L.R. Le Nail, M. Jafari, J.-C. Ruzic, O. Marco, F. Gouin, G. Vaz, A. Dupré, P. Anract, E. Stoeckle, A. Michot, F. Dujardin, Jean-Yves Blay, Emmanuelle Bompas, F. Guillemin, C. Honore, F. Duffaud, P. Meeus, A. Rochwerger, Nicolas Penel, F. Fiorenza, F. Le Loarer, S. Bonvalot, Mickaël Ropars, A. Le Cesne, F. Ducimetière, D. Pérol, A. Italiano, F. Marchal, P. Soibinet, Sébastien Carrère, J.-C. Machiavello, A. Giraud, François Bertucci, N. Firmin, M. Brahmi, AIRPARIF - Surveillance de la qualité de l'air en Île-de-France, Institut Bergonié - CRLCC Bordeaux, Centre Léon Bérard [Lyon], Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de recherche en Hydrodynamique, Énergétique et Environnement Atmosphérique (LHEEA), École Centrale de Nantes (ECN)-Centre National de la Recherche Scientifique (CNRS), Centre chirurgical Émile-Gallé, Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Department of Surgical Oncology, Jean Perrin Comprehensive Cancer Centre, Service de Chirurgie orthopédique et traumatologique [CHU Limoges], CHU Limoges, Service d'oncologie Médicale, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Laboratoire de Chimie et Physique - Approche Multi-échelle des Milieux Complexes (LCP-A2MC), CHU Pitié-Salpêtrière [APHP], Institut Claudius Regaud, CRLCC Institut Claudius Regaud, Oncogenesis Stress Signaling (OSS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CRLCC Eugène Marquis (CRLCC), Département de radiothérapie [Gustave Roussy], Institut Gustave Roussy (IGR), Centre de Recherches sur les Macromolécules Végétales (CERMAV), Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Laboratoire Interdisciplinaire de Recherche Impliquant la Géologie et la Mécanique, Université Joseph Fourier - Grenoble 1 (UJF), Centre Oscar Lambret, Laboratoire des Mécanismes et Transfert en Géologie (LMTG), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Observatoire Midi-Pyrénées (OMP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, medicine.medical_specialty, Multivariate analysis, [SDV]Life Sciences [q-bio], medicine.medical_treatment, [SDV.CAN]Life Sciences [q-bio]/Cancer, Relapse free survival, 03 medical and health sciences, 0302 clinical medicine, medicine, Neurofibromatosis, Pathological, ComputingMilieux_MISCELLANEOUS, business.industry, Hazard ratio, Cancer, Hematology, medicine.disease, 3. Good health, Surgery, Radiation therapy, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Sarcoma, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Background NETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB and expert pathological review are mandatory for sarcoma patients nationwide. In the present work, the impact of surgery in a reference center on the survival of sarcoma patients investigated using this national NETSARC registry. Patients and methods Patients’ characteristics and follow-up are prospectively collected and data monitored. Descriptive, uni- and multivariate analysis of prognostic factors were conducted in the entire series (N = 35 784) and in the subgroup of incident patient population (N = 29 497). Results Among the 35 784 patients, 155 different histological subtypes were reported. 4310 (11.6%) patients were metastatic at diagnosis. Previous cancer, previous radiotherapy, neurofibromatosis type 1 (NF1), and Li–Fraumeni syndrome were reported in 12.5%, 3.6%, 0.7%, and 0.1% of patients respectively. Among the 29 497 incident patients, 25 851 (87.6%) patients had surgical removal of the sarcoma, including 9949 (33.7%) operated in a NETSARC center. Location, grade, age, size, depth, histotypes, gender, NF1, and surgery outside a NETSARC center all correlated to overall survival (OS), local relapse free survival (LRFS), and event-free survival (EFS) in the incident patient population. NF1 history was one of the strongest adverse prognostic factors for LRFS, EFS, and OS. Presentation to an MDTB was associated with an improved LRFS and EFS, but was an adverse prognostic factor for OS if surgery was not carried out in a reference center. In multivariate analysis, surgery in a NETSARC center was positively correlated with LRFS, EFS, and OS [P

Published
2019

3. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy

Author

Serge Koscielny, François Eschwege, Pierre Wibault, Khemaies Slimane, Alberto Bossi, T. Messai, R. de Crevoisier, André Bridier, Karim Fizazi, Christophe Massard, Service de radiothérapie, CRLCC Eugène Marquis (CRLCC), Département de radiothérapie [Gustave Roussy], Institut Gustave Roussy (IGR), Département de médecine oncologique [Gustave Roussy], Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], and Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR)

Subjects
Male, androgen deprivation, MESH: Combined Modality Therapy, Time Factors, MESH: Treatment Failure, medicine.medical_treatment, Brachytherapy, 030232 urology & nephrology, urologic and male genital diseases, MESH: Down-Regulation, Androgen deprivation therapy, Prostate cancer, MESH: Aged, 80 and over, 0302 clinical medicine, MESH: Early Diagnosis, Prostate, Treatment Failure, Antiandrogen Therapy, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, Hematology, Middle Aged, MESH: Antineoplastic Agents, Hormonal, Prognosis, prostate cancer, Combined Modality Therapy, MESH: Prostate-Specific Antigen, 3. Good health, MESH: Androgen Antagonists, Prostate-specific antigen, medicine.anatomical_structure, Oncology, MESH: Survival Analysis, 030220 oncology & carcinogenesis, [SDV.IB]Life Sciences [q-bio]/Bioengineering, MESH: Brachytherapy, medicine.medical_specialty, Antineoplastic Agents, Hormonal, Urology, Down-Regulation, [SDV.CAN]Life Sciences [q-bio]/Cancer, Adenocarcinoma, MESH: Prognosis, 03 medical and health sciences, MESH: Prostatectomy, medicine, Humans, External beam radiotherapy, radiotherapy, Aged, Retrospective Studies, Prostatectomy, MESH: Humans, business.industry, MESH: Adenocarcinoma, MESH: Time Factors, Prostatic Neoplasms, Cancer, Androgen Antagonists, MESH: Retrospective Studies, Prostate-Specific Antigen, medicine.disease, Survival Analysis, MESH: Male, Surgery, Radiation therapy, Early Diagnosis, MESH: Prostatic Neoplasms, business
Abstract

International audience; BACKGROUND: The aim was to identify predictors of outcome in patients with localized prostate cancer treated with external beam radiotherapy (EBRT), with or without androgen deprivation therapy (ADT). Materials and methods: A total of 448 patients with prostate cancer received EBRT alone (n = 361, group 1) or ADT followed by EBRT (n = 87, group 2). In group 2, ADT was initiated 3 months before EBRT. After baseline prostate-specific antigen (PSA) determination (PSA(preRT)), PSA was assessed during the 6th week of the EBRT course (PSA(6wRT)) in group 1. In group 2, PSA was measured again 3 months after the start of ADT, before EBRT (PSA(ADT-preRT)). RESULTS: In group 1, median PSA(6wRT)/PSA(preRT) was 0.72 and median prostate-specific antigen velocity (PSAV) was -1.5 ng/ml/month. In the multivariate analysis, prognostic groups and PSA(6wRT)/PSA(preRT) (or PSAV) independently predicted biochemical failure (BF), clinical failure (CF), and prostate cancer-specific survival. In group 2, the median PSA(ADT-preRT) was 1.3 ng/ml. In the high-risk group, an undetectable PSA(ADT-preRT) (< or =0.2 ng/ml) predicted BF (P < 0.01) and CF (P = 0.007). CONCLUSION: A PSA decline 6 weeks after the start of EBRT when used as monotherapy and 3 months after the start of ADT in patients treated with combined ADT and EBRT is predictive of progression and specific survival.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results